drugset / Trial / NCT05055414
Arformoterol/Budesonide for COVID-19
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase 2 study to evaluate the efficacy and safety of UI030 in COVID-19 patients
Timeline
- Start
- 2021-11-01
- Primary completion
- 2022-10-01
- Completion
- 2022-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arformoterol | Small molecule | — | Inhaled |
| Subject | Budesonide | Small molecule | — | Inhaled |